ABSTRACT Trisomy 11 in myelodysplastic syndromes (MDS) is rare, with undefined clinical significance and is currently assigned to the International Prognostic Scoring System (IPSS)

intermediate-risk group. Over a 15-year period, we identified 17 MDS patients with trisomy 11 either as a sole abnormality (_n_=10) or associated with one or two additional alterations

(_n_=7), comprising 0.3% of all MDS cases reviewed. Of 16 patients with Bone Marrow material available for review, 14 (88%) patients presented with excess blasts, 69% patients evolved to

acute myeloid leukemia (AML) in a 5-month median interval and the median survival was 14 months. For comparison, we studied 19 AML patients with trisomy 11 in a noncomplex karyotype, of

comprising 1165 MDS patients, MDS patients with trisomy 11 had a significantly inferior survival to patients in the IPSS intermediate-risk cytogenetic group (_P_=0.0002), but comparable to

the poor-risk group (_P_=0.97). We conclude that trisomy 11 in MDS correlates with clinical aggressiveness, may suggest an early/evolving AML with myelodysplasia-related changes and is best

considered a high-risk cytogenetic abnormality in MDS prognostication. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution

ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Learn more Buy this article *

Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn

about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS-UNCLASSIFIABLE WITH ISOLATED

ISOCHROMOSOME 17Q REPRESENTS A DISTINCT CLINICO-BIOLOGIC SUBSET: A MULTI-INSTITUTIONAL COLLABORATIVE STUDY FROM THE BONE MARROW PATHOLOGY GROUP Article 13 November 2021 MYELOID NEOPLASMS

ASSOCIATED WITH T(3;12)(Q26.2;P13) ARE CLINICALLY AGGRESSIVE, SHOW MYELODYSPLASIA, AND FREQUENTLY HARBOR CHROMOSOME 7 ABNORMALITIES Article 27 October 2020 MYELODYSPLASTIC SYNDROME WITH

T(6;9)(P22;Q34.1)/_DEK-NUP214_ BETTER CLASSIFIED AS ACUTE MYELOID LEUKEMIA? A MULTICENTER STUDY OF 107 CASES Article 08 February 2021 REFERENCES * Slovak ML, Traweek ST, Willman CL, Head DR,

Kopecky KJ, Magenis RE _et al_. Trisomy 11: an association with stem/progenitor cell immunophenotype. _Br J Haematol_ 1995; 90: 266–273. Article  CAS  Google Scholar  * Sierra M, Hernandez

JM, Garcia JL, Gutierrez NC, Perez JJ, Vidriales MB _et al_. Hematological, immunophenotypic, and cytogenetic characteristics of acute myeloblastic leukemia with trisomy 11. _Cancer Genet

Cytogenet_ 2005; 160: 68–72. Article  CAS  Google Scholar  * Caligiuri MA, Strout MP, Schichman SA, Mrozek K, Arthur DC, Herzig GP _et al_. Partial tandem duplication of ALL1 as a recurrent

molecular defect in acute myeloid leukemia with trisomy 11. _Cancer Res_ 1996; 56: 1418–1425. CAS  PubMed  Google Scholar  * Bernard OA, Romana SP, Schichman SA, Mauchauffe M, Jonveaux P,

Berger R . Partial duplication of HRX in acute leukemia with trisomy 11. _Leukemia_ 1995; 9: 1487–1490. CAS  PubMed  Google Scholar  * Schichman SA, Caligiuri MA, Gu Y, Strout MP, Canaani E,

Bloomfield CD _et al_. ALL-1 partial duplication in acute leukemia. _Proc Natl Acad Sci USA_ 1994; 91: 6236–6239. Article  CAS  Google Scholar  * Rege-Cambrin G, Giugliano E, Michaux L,

Stul M, Scaravaglio P, Serra A _et al_. Trisomy 11 in myeloid malignancies is associated with internal tandem duplication of both MLL and FLT3 genes. _Haematologica_ 2005; 90: 262–264. CAS 

PubMed  Google Scholar  * Collado R, Badia L, Garcia S, Sanchez H, Prieto F, Carbonell F . Chromosome 11 abnormalities in myelodysplastic syndromes. _Cancer Genet Cytogenet_ 1999; 114:

58–61. Article  CAS  Google Scholar  * Gangji D, Noseda A, Wybran J, Verhest A . Trisomy 11 in preleukemia. _Cancer Genet Cytogenet_ 1985; 14: 119–123. Article  CAS  Google Scholar  * Morgan

R, Greene MH, Sandberg AA . Trisomy 11 in myelodysplasia. _Cancer Genet Cytogenet_ 1988; 30: 159–162. Article  CAS  Google Scholar  * Takasaki N, Kaneko Y, Maseki N, Sakurai M . Trisomy 11

in chronic myelomonocytic leukemia: report of two cases and review of the literature. _Cancer Genet Cytogenet_ 1988; 30: 109–117. Article  CAS  Google Scholar  * Weh HJ, Hoffmann R, Suciu S,

Kuse R, Hossfeld DK . Is trisomy 11 another nonrandom chromosomal anomaly in acute nonlymphocytic leukemia and myelodysplastic syndromes? _Cancer Genet Cytogenet_ 1988; 35: 205–211. Article

  CAS  Google Scholar  * Yamamoto K, Hamaguchi H, Nagata K, Kobayashi M, Taniwaki M . Tandem duplication of the _MLL_ gene in myelodysplastic syndrome-derived overt leukemia with trisomy 11.

_Am J Hematol_ 1997; 55: 41–45. Article  CAS  Google Scholar  * Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G _et al_. International scoring system for evaluating prognosis in

myelodysplastic syndromes. _Blood_ 1997; 89: 2079–2088. CAS  PubMed  Google Scholar  * Pozdnyakova O, Miron PM, Tang G, Walter O, Raza A, Woda B _et al_. Cytogenetic abnormalities in a

series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. _Cancer_ 2008; 113: 3331–3340. Article

  Google Scholar  * Brunning B, Orazi A, Germing U, Le Beau M, Porwit A, Baumann I _et al_. _Myelodysplastic Syndromes/Neoplasms_, vol. 2008. IARC Press: Lyon, 2008. Google Scholar  *

Gustincich S, Manfioletti G, Del Sal G, Schneider C, Carninci P . A fast method for high-quality genomic DNA extraction from whole human blood. _Biotechniques_ 1991; 11: 298–300, 302. CAS 

PubMed  Google Scholar  * Caligiuri MA, Schichman SA, Strout MP, Mrozek K, Baer MR, Frankel SR _et al_. Molecular rearrangement of the _ALL-1_ gene in acute myeloid leukemia without

cytogenetic evidence of 11q23 chromosomal translocations. _Cancer Res_ 1994; 54: 370–373. CAS  PubMed  Google Scholar  * Lin P, Jones D, Medeiros LJ, Chen W, Vega-Vazquez F, Luthra R .

Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. _Am J Clin Pathol_ 2006; 126: 530–533.

Article  CAS  Google Scholar  * Zuo Z, Chen SS, Chandra PK, Galbincea JM, Soape M, Doan S _et al_. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. _Mod

Pathol_ 2009; 22: 1023–1031. Article  CAS  Google Scholar  * Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B _et al_. New insights into the prognostic impact of the

karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. _Blood_ 2007; 110: 4385–4395. Article  CAS  Google Scholar  * Bernasconi P, Klersy C, Boni M,

Cavigliano PM, Calatroni S, Giardini I _et al_. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with _de

novo_ primary myelodysplastic syndromes. _Br J Haematol_ 2007; 137: 193–205. Article  CAS  Google Scholar  * Steudel C, Wermke M, Schaich M, Schakel U, Illmer T, Ehninger G _et al_.

Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. _Genes Chromosomes Cancer_ 2003; 37:

237–251. Article  CAS  Google Scholar  * Shiah HS, Kuo YY, Tang JL, Huang SY, Yao M, Tsay W _et al_. Clinical and biological implications of partial tandem duplication of the MLL gene in

acute myeloid leukemia without chromosomal abnormalities at 11q23. _Leukemia_ 2002; 16: 196–202. Article  CAS  Google Scholar  * Schnittger S, Kinkelin U, Schoch C, Heinecke A, Haase D,

Haferlach T _et al_. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. _Leukemia_ 2000; 14: 796–804. Article  CAS

  Google Scholar  * Caligiuri MA, Strout MP, Oberkircher AR, Yu F, de la Chapelle A, Bloomfield CD . The partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics

or trisomy 11 is restricted to one chromosome. _Proc Natl Acad Sci USA_ 1997; 94: 3899–3902. Article  CAS  Google Scholar  * Schnittger S, Wormann B, Hiddemann W, Griesinger F . Partial

tandem duplications of the _MLL_ gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. _Blood_ 1998; 92: 1728–1734. CAS  PubMed  Google Scholar  * Dorrance

AM, Liu S, Chong A, Pulley B, Nemer D, Guimond M _et al_. The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele.

_Blood_ 2008; 112: 2508–2511. Article  CAS  Google Scholar  * Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K _et al_. DNA hypermethylation and epigenetic silencing of

the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. _Blood_ 2008; 112: 2013–2016. Article  CAS  Google Scholar  * de Souza Fernandez T,

Menezes de Souza J, Macedo Silva ML, Tabak D, Abdelhay E . Correlation of N-ras point mutations with specific chromosomal abnormalities in primary myelodysplastic syndrome. _Leuk Res_ 1998;

22: 125–134. Article  CAS  Google Scholar  * Langabeer SE, Beghini A, Larizza L . AML with t(8;21) and trisomy 4: possible involvement of c-kit? _Leukemia_ 2003; 17: 1915; author reply

1915–1916. Article  CAS  Google Scholar  * Bacher U, Haferlach T, Kern W, Weiss T, Schnittger S, Haferlach C . The impact of cytomorphology, cytogenetics, molecular genetics, and

immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes. _Cancer_ 2009; 115: 4524–4532. Article  Google Scholar  Download references ACKNOWLEDGEMENTS We thank Dr

Hwei-Fang Tien and her assistant Shau-Chi at the National Taiwan University Hospital, Taipei, Taiwan for the technical support in _MLL_ PTD study using genomic DNA PCR. AUTHOR INFORMATION

AUTHORS AND AFFILIATIONS * Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA S A Wang, K Jabbar, G Lu, S S Chen, F Vega, D Jones, T J

McDonnell & L J Medeiros * Department of Internal Medicine, St Vincent's Comprehensive Cancer Center, New York, NY, USA N Galili & A Raza * Department of Leukemia, The

University of Texas MD Anderson Cancer Center, Houston, TX, USA H Kantarjian & G Garcia-Manero Authors * S A Wang View author publications You can also search for this author inPubMed 

Google Scholar * K Jabbar View author publications You can also search for this author inPubMed Google Scholar * G Lu View author publications You can also search for this author inPubMed 

Google Scholar * S S Chen View author publications You can also search for this author inPubMed Google Scholar * N Galili View author publications You can also search for this author

inPubMed Google Scholar * F Vega View author publications You can also search for this author inPubMed Google Scholar * D Jones View author publications You can also search for this author

inPubMed Google Scholar * A Raza View author publications You can also search for this author inPubMed Google Scholar * H Kantarjian View author publications You can also search for this

author inPubMed Google Scholar * G Garcia-Manero View author publications You can also search for this author inPubMed Google Scholar * T J McDonnell View author publications You can also

search for this author inPubMed Google Scholar * L J Medeiros View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to S A

Wang. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no conflict of interest. ADDITIONAL INFORMATION Supplementary Information accompanies the paper on the Leukemia website

SUPPLEMENTARY INFORMATION SUPPLEMENTARY TABLE 1 (DOC 63 KB) SUPPLEMENTARY TABLE 2 (DOC 101 KB) RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Wang, S.,

Jabbar, K., Lu, G. _et al._ Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. _Leukemia_ 24, 740–747 (2010).

https://doi.org/10.1038/leu.2009.289 Download citation * Received: 09 November 2009 * Accepted: 23 November 2009 * Published: 14 January 2010 * Issue Date: April 2010 * DOI:

https://doi.org/10.1038/leu.2009.289 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * myelodysplastic syndrome * trisomy 11 * acute myeloid

leukemia * overall survival * _MLL_ partial tandem duplication